TNFRSF8 and classic Hodgkin lymphoma: In the first published phase I trial of an anti-CD30 CAR T-cell product, 17 patients with R/R cHL and one patient with anaplastic large cell lymphoma were treated, showing 39% of ORR and a median PFS of 6 months [151].